Cytorex releases study of effectiveness of Cytoreg® in B15F1 Melanona in female mice

DAVIE, Fla. - Nov. 16, 2014 - PRLog -- Cytorex Biosciences Inc., a South Florida based biopharmaceutical  company,  announced today the publication of a study related the effectiveness  of Cytoreg®, their lead compound, against Melanoma in C57BL / 6 // BIO  female mice.

The study was published in the RETEL Online Journal of Toxicology of the Children Sanatorium of the Republic of Argentina, a part of the agreement between Cytorex de Venezuela S.A., and BIOULA, the Biotechnology Research Lab of the University of Los Andes (ULA), located in Merida, Venezuela.

During the research stage, water and food consumption, body weight, and tumor size were assessed on a daily basis. Additionally,  hematological parameters such as leukocytes, hematocrits, and incremental count were measured, and it was determined that the antineoplastic agent Cytoreg® stimulated an increase in the concentration of leucocytes, did not alter the percentages of hematocrits, and increased the percentages of neutrophils,  neutrophils, monocytes, basophils and eosinophils. In animals treated with Cytoreg®, tumor size was similar than in those animals treated with the Standard of Care available in the market for Melanoma.

“It was also established that Cytoreg® is not only effective for the treatment of Melanoma B15F1, but did not produce toxicity in the test animals treated with the agent”, indicated William Jimenez, Vice-President of Cytorex Biosciences, Inc.,  and coauthor  of the study.

“It is noteworthy, that the R&D agreement between Cytorex and ULA, has allowed us to complete in Venezuela the preclinical development of Cytoreg®, a 100% Venezuelan invention.  Currently, we are in the process of data tabulation and analysis for reporting the results of other scientific studies with Cytoreg®, with the purpose of submitting these results to peer-reviewed journals for publication. These studies are related to Acute and Chronic toxicity in rats, Pharmacology in rabbits and rats, and histological and pathological reports of antitumor efficacy of Cytoreg® in these animal models, as well as determination of mechanisms of action” concluded Jimenez.

William Jimenez informed that the company has plans to fund additional studies in in other countries such as the USA and Canada, with the purpose of submitting an IND (Investigational New Drug) application with the Food and Drug Administration in the near future.

Cytoreg® is defined as a non-molecular, ionic therapy derived from a perfectly balanced mix of strong and weak acids (ion equilibrium), a complex ion transport (electrons) in high concentrations to help regulate the mitochondrial and cellular metabolism. Cytoreg® is of very low molecular weight, and (undiluted) has a pH of less than 1. Among several mechanisms of action already discovered we can mention the selective induction of apoptosis (death) in cancer cells.

The WHO (World Health Organization) has indicated that cancer is a leading cause of death worldwide.  In 2008 alone, cancer caused 7.6 million deaths (around 13% of Total Deaths), and that approximately 70% of cancer deaths in the year 2008 occurred in low- and middle-income persons.

The WHO predicts that cancer deaths continue to rise around the world and that it will reach 13.1 million in 2030

Link to the publication:   http://www.sertox.com.ar/img/item_full/43003.pdf

FOR MORE INFORMATION, PLEASE CONTACT:

Cytorex Biosciences, Inc.
 4474 Weston Road No. 108
 Weston, FL 33331

Mr. William J. Jimenez,
Vice -President
Email: wjimenez@cytorex.com
+58 414 614 0226 / +1 786 284 2759

Carlos M. Garcia
Managing Director and COO
email: cmgarcia@cytorex.com
+ 1 954 573 4006